top of page
Science Student
Closeup of a Petri Dish

Hacking the cellular messenger system

Welcome. We’re EVIIVE, and we’re disrupting the diagnostics industry with our groundbreaking solutions and business ideas.

Home: Welcome

ABOUT US

We are developing novel liquid biopsies biomarkers discovery platform and assay kit provider for personalized treatment guidance and disease progression monitoring.

 

With our innovative and insightful technology, we strive to enhance personalized diagnostics. Founded in 2022, our incredible team of research experts have worked tirelessly to bring EVIIVE to the forefront of the Medtech industry.

 

We have, and will continue to work tirelessly to become the technological standard, providing big picture insights which industry leaders not only approve of, but also depend on. 

Experiment
Home: About Us
KY1_edited.png

Dr Kevin Yim

Co-Founder & CEO

RC2_edited.jpg

Prof Dr Richard Chahwan

Co-Founder & CSO

Home: Our Team

OUR INNOVATIVE TECHNOLOGY

At EVIIVE, our novel technological solutions help industry leading companies and individuals achieve greater diagnostic and prognostic power. Our platform has a wide range of features that were created with an aim to help personlize patient care in a quick and effective manner. In order to empower our patients to do better, EVIIVE is continually building upon its technology, so stay in touch to learn about upgrades and other changes. 

Scientist Pipetting
Home: Our Technology
Embryonic Stem Cells

PIPELINE

Stay tuned for our upcoming pipeline

Home: Quote

IN THE PRESS

Making Headlines

EVIIVE WINS VENTURE KICK FUNDING

28.12.2022

Startups developing a low-cost breathe ventilator, 300x faster qubits, a minimally invasive diagnostic for sepsis, sustainable real estate investment, sustainable food based on fungi and fermantation each win Venture Kick funds. News Link.

EVIIVE WINS MEDTECH FELLOWSHIP

01.06.2022

EVIIVE wins the UZH-BIOMEDTECH fellowship supported by the WSS foundation. And EVIIVE is offered lab space at IREM-Schlieren supported by the WYSS foundation. News Link.

NEW METHODOLOGY CHANGING DIAGNOSTICS

24.01.2022

Our proof of concept approach to use extracellular vesicles to detect SARS-CoV-2 infection, immune response status, and immune system effects. News Link.

Home: News

GET IN TOUCH

Wintethurerstrasse 190, Irchel Y23K74, Zurich 8057, CH

+41 446353710

  • LinkedIn

Thanks for submitting!

Home: Contact
bottom of page